Bajaj Healthcare gets rights to manufacture, distribute, sell Magnesium L Threonate in India
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2025-01-18 07:00 GMT | Update On 2025-01-18 07:00 GMT
Mumbai: Bajaj Healthcare Limited has announced that it has received exclusive rights for manufacturing, distribution and sales of the finished formulation of the Product Magnesium L Threonate (Magtein) in India from the rights holder, Threotech LLC.
Threotech LLC has granted Bajaj Healthcare Limited the licensing rights to manufacture finished formulation of Magnesium L Threonate (Magtein) along with the rights to enter into marketing collaborations with leading branded pharmaceutical firms for the Indian market.
Bajaj Healthcare Limited will therefore have the rights to manufacture/ market/ distribute/co-market in the Indian market for Magnesium L Threonate (Magtein).
The Company is already supplying the API Magnesium L Threonate (Magtein), to the patent holder in United States of America. The API is supplied by Bajaj Healthcare Ltd. for the brand Magtein in the United States of America as an exclusive arrangement.
The brand Magtein by Threotech LLC has a sales value of approx. USD 438 million.
Speaking at the occasion, Anil Jain, Managing Director, Bajaj Healthcare Limited, said, “Our collaboration with Threotech LLC has taken an exciting step forward after receiving licensing rights for manufacturing, marketing and selling their innovative product, Magtein, in India. With our strong domestic presence and proven manufacturing & distribution expertise, we are well-positioned to unlock the product’s full potential in the Indian market. This development reaffirms our position as a trusted partner to our international clients and underscores our ability to seamlessly integrate manufacturing & quality excellence with strategic market outreach.”
Established in 1993, Bajaj Healthcare Limited is a Manufacturer of APIs, Intermediates and Formulations. It specializes in manufacturing of intermediates, API, formulations & Nutraceuticals. The Company has state-of-art manufacturing facilities of APIs, intermediates and formulations. These facilities are designed to meet the requirements of both advanced as well as emerging market opportunities. BHL has a presence globally in countries like Europe, USA, Australia, Middle East and South America.
Read also: Bajaj Healthcare enters into CDMO contract with UK/EU-based companies for 15 new APIs
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.